These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22783345)

  • 1. Hepatitis B Virus Genotype B and High Expression of Interferon Alpha Receptor β Subunit are Associated With Better Response to Pegylated Interferon Alpha 2a in Chinese Patients With Chronic Hepatitis B Infection.
    Fan HB; Guo YB; Zhu YF; Chen AS; Zhou MX; Li Z; Xu LT; Ma XJ; Yan FM
    Hepat Mon; 2012 May; 12(5):333-8. PubMed ID: 22783345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy.
    Cao W; Lu H; Zhang L; Wang S; Deng W; Jiang T; Lin Y; Yang L; Bi X; Lu Y; Zhang L; Shen G; Liu R; Chang M; Wu S; Gao Y; Hao H; Xu M; Chen X; Hu L; Xie Y; Li M
    Front Immunol; 2022; 13():1067362. PubMed ID: 36479104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association study of IFNAR2 and IL10RB genes with the susceptibility and interferon response in HBV infection.
    Gong QM; Kong XF; Yang ZT; Xu J; Wang L; Li XH; Jin GD; Gao J; Zhang DH; Jiang JH; Lu ZM; Zhang XX
    J Viral Hepat; 2009 Sep; 16(9):674-80. PubMed ID: 19714778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of nucleoside analogues to peg-IFNα-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFNα-2a: a randomized controlled trial.
    Xu Y; Wang X; Liu Z; Zhou C; Qi W; Jiao J; Yu F; Guo H; Zhao P; Wang J
    BMC Gastroenterol; 2017 Aug; 17(1):102. PubMed ID: 28854883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of double filtration plasmapheresis with pegylated interferon/ribavirin therapy for intractable chronic hepatitis C patients and hepatitis C patients with combined liver cirrhosis by HBV, leading to early viral elimination.
    Ohara T; Oteki T; Suzuki T; Suzuki M; Matsuzaki Y
    Hepatogastroenterology; 2011; 58(105):133-6. PubMed ID: 21510300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
    Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
    Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver.
    Fukuda R; Ishimura N; Hamamoto S; Moritani M; Uchida Y; Ishihara S; Akagi S; Watanabe M; Kinoshita Y
    J Med Virol; 2001 Mar; 63(3):220-7. PubMed ID: 11170061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of combination therapy with ME3738 and pegylated interferon-alpha-2a in patients with hepatitis C virus genotype 1.
    Saibara T; Enomoto N; Kaneko S; Chayama K; Sata M; Imawari M; Onishi S; Okita K
    Hepatol Res; 2014 Apr; 44(4):410-9. PubMed ID: 23607362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Add-on pegylated interferon augments hepatitis B surface antigen clearance
    Wu FP; Yang Y; Li M; Liu YX; Li YP; Wang WJ; Shi JJ; Zhang X; Jia XL; Dang SS
    World J Gastroenterol; 2020 Apr; 26(13):1525-1539. PubMed ID: 32308352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes.
    Boglione L; D'Avolio A; Cariti G; Milia MG; Simiele M; De Nicolò A; Ghisetti V; Di Perri G
    J Viral Hepat; 2013 Apr; 20(4):e11-9. PubMed ID: 23490378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience.
    Bahcecioglu IH; Ispiroglu M; Demirel U; Yalniz M
    Hepat Mon; 2015 Mar; 15(3):e24366. PubMed ID: 25861318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow up of peginterferon-α-2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies.
    Okanoue T; Shima T; Hasebe C; Karino Y; Imazeki F; Kumada T; Minami M; Imai Y; Yoshihara H; Mita E; Morikawa T; Nishiguchi S; Kawakami Y; Nomura H; Sakisaka S; Kurosaki M; Yatsuhashi H; Oketani M; Kohno H; Masumoto A; Ikeda K; Kumada H
    Hepatol Res; 2016 Sep; 46(10):992-1001. PubMed ID: 26670363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
    Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H
    World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of peginterferon alpha-2a vs. interferon alpha-2a on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients.
    Liu S; Zheng H; Huang Y; Li B; Dong Z
    Clin Res Hepatol Gastroenterol; 2016 Jun; 40(3):304-308. PubMed ID: 26382279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
    Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
    Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.